Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

OSE Immunotherapeutics (PAR: OSE) – AbbVie partnership amendment >

Arron Aatkar, PhD | Healthcare | Comment | 21 hours ago

OSE Immunotherapeutics (PAR: OSE) – AbbVie partnership amendment >

Arron Aatkar, PhD | Healthcare | Comment | 21 hours ago

SEE ALL COMMENTARY >

Actinogen Medical (ACW)

Latest price

AUD0.05

— 0.00 (−7.02)

As at 08/12/2025

Market capitalisation: AUD169m

Equities

Equities by Sector

Sectors

Thematics

Latest

Digital assets – Part 5: Digital asset treasury companies

Edison explains: UK Budget – Why the market rallied despite the tax grab

Digital assets – Part 4: Asset tokenisation and payments

Audiovisual

Latest

Ovanti – executive interview

In the chair with bp’s Craig Marshall: From bp’s biggest find in 25 years to value creation

BlackRock Latin American Investment Trust – equity proposition

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.05

Actinogen Medical — XanaMIA passes first safety milestone

Actinogen Medical — XanaMIA recruitment exceeds expectations

Actinogen Medical — An eventful period ahead for Xanamem

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.60

AFT Pharmaceuticals — Making progress on growth strategy

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

See morecontent on

Alzinova (ALZ)

SEK1.71

Webinar: The CNS renaissance Biotech companies at the forefront

Alzinova — Innovative new approach to Alzheimer's

See morecontent on

AOTI (AOTI)

GBP0.34

Argent Biopharma (RGT)

AUD0.07

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF52.40

Basilea Pharmaceutica — BARDA backs latest antibacterial programme

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Gearing up for the next growth phase

See morecontent on

Biomea Fusion (BMEA)

USD1.35

Biomea Fusion — An innovative approach to diabetes and obesity

See morecontent on

BioVersys (BIOV)

CHF23.10

Cantargia (CANTA)

SEK3.82

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK8.34

Cereno Scientific — Armed and ready for Phase II

Cereno Scientific – executive interview

Cereno Scientific – executive interview

See morecontent on

Chosa (CHOSA)

SEK0.86

CHOSA Oncology – executive interview

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

See morecontent on

Creo Medical (CREO)

GBP0.10

Creo Medical — H1 momentum underpins FY25 confidence

Creo Medical — SpydrBlade Flex set to enter the US market

Creo Medical – executive interview

See morecontent on

Diamyd Medical (DMYD)

SEK9.37

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on